Home PROTAC Molecule MDM2/PROTAC
In the latest edition of Cancer Discovery, Adams and his team unveil a potent proteolysis-targeting chimera (PROTAC), an MDM2 degrader that activates wild-type p53, ultimately inducing cell death in cancer cells. Significantly, through a series of in vitro and in vivo experiments, the authors demonstrate that the depletion of MDM2 by PROTAC effectively eliminates p53-mutant or p53-null cancer cells.
By Route Intermediates+−
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :